CVM

$3.60

Market ClosedAs of Mar 17, 8:00 PM UTC

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Intraday

Custom Range:
to
No data available for this range. Intraday data may be limited by the exchange.

Recent News

Associated Press Finance
Feb 17, 2026

Cel-Sci: Fiscal Q1 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Tuesday reported a loss of $5.5 million in its fiscal first quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
Aug 14, 2025

Cel-Sci: Fiscal Q3 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Thursday reported a loss of $5.7 million in its fiscal third quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
May 14, 2025

Cel-Sci: Fiscal Q2 Earnings Snapshot

VIENNA, Va. AP) — Cel-Sci Corp. CVM) on Wednesday reported a loss of $6.6 million in its fiscal second quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.